



Feb 6, 2014, Ghent University Hospital campus
<http://mellfire.ugent.be/public/oncopoint/>

- 8.45-9.00 **Opening**
- 09.00-09.20 **Selected abstract presentations**
A novel MYCN/ miR-26a-5p/ LIN28B regulatory axis underlies MYCN -driven LIN28B upregulation during mouse neuroblastoma development
Beckers Anneleen
- 09.20-09.40 *SOX11 is a lineage-survival oncogene in neuroblastoma*
Decaesteker Bieke
- 09.40-10.00 *Micro-particle encapsulated carcinoma-associated fibroblast (CAF) deceive and redirect disseminated cancer cells*
De Vlieghere Elly
- 10.00-10.40 **Short abstract presentations**
- 10.40-11.00 **Coffee break**
- 11.00-11.20 **Selected abstract presentations**
MicroRNA-128-3p is a novel oncomir targeting PHF6 in T-cell acute lymphoblastic leukemia
Mets Evelien
- 11.20-11.40 *Optimalization and characterization of a novel intraductal mouse mammary tumor model*
Meyer Evelyne
- 11.40-12.00 *Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression*
Denecker Geertrui
- 12.00-12.40 **Short abstract presentations**
- 12.40-13.30 **Lunch**

Selected abstract presentations

13.30-13.50 *The bubble breakthrough in cancer immunotherapy: the use of mrna sonoporation in dendritic cell-based cancer vaccination*
Dewitte Heleen

13.50-14.10 *A comparative study of four isolation methods for exosomes from cell culture models*
Van Deun Jan

14.10-14.30 *Expanding the TLX1-regulome in T-cell acute lymphoblastic leukemia towards long non-coding RNAs*
Durinck Kaat

14.30-14.50 *A model-based analysis of IPEC dosing of paclitaxel in rats: "less is more"*
Colin Pieter

14.50-15.10 *LncRNA expression landscaping in cancer identifies novel lineage survival oncogenes in melanoma*
Mestdagh Pieter

15.10-15.30 *Green tea compound EGCG activates HBP1: an ALK downstream suppressor gene in neuroblastoma*
Claeys Shana

15.30-15.50 *ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in early immature T-cell acute lymphoblastic leukemia*
Peirs Sofie

15.50-16.10 **Coffee break**

Selected abstract presentations

16.10-16.30 *Metastasis-directed therapy for oligometastatic recurrence in non-castrate prostate cancer patients*
Claeys Tom

16.30-16.50 *Role of NANOS family members in tumor progression*
Andries Vanessa

16.50-17.10 *Temporal dynamics and therapeutic potential of the unfolded protein response in hepatocellular carcinoma*
Vandewynckel Yves-Paul

17.10-17.50 **Short abstract presentations**

17.50-18.05 **Final conclusions, announcements of awards**

18.05-end **Communicake** (drinks, cake, and communication)

10.00-10.40 **Short abstract presentations**

- Pottel Lies** Serial Comprehensive Geriatric Assessment in elderly head and neck cancer patients indicates quality of life during and after curative radiotherapy (abstract 17)
- Lycke Michelle** Validation of the Freund Clock Drawing Test as a screening tool to detect cognitive dysfunction in elderly cancer patients undergoing Comprehensive Geriatric Assessment. (abstract 18)
- Tommelein Joke** Radiation-induced changes in carcinoma-associated fibroblasts: consequences for fibrosis and colorectal cancer progression (abstract 19)
- Van Nieuwenhuysen Tom** TALEN mediated disruption of Adenomatous Polyposis Coli in Xenopus as a model for Wnt driven tumorigenesis (abstract 20)
- Bracke Nathalie** The possible role of somatropin derivatives as a theranostic in oncology (abstract 21)
- Van Troys Marleen** TUMOR CELL INVASION DYNAMICS IN 3D-MATRICES: QUANTATIVE ANALYSIS USING THE CELLMIA-CellMissy SOFTWARE TANDEM (abstract 22)
- Vermassen Tijl** Prostate proteins glycosylation profile as a potential diagnostic biomarker for prostate cancer (abstract 23)
- Cicchelero Laetitia** Preparation and characterization of a cancer vaccine composed of immunogenically killed tumor cells and dendritic cells (abstract 24)
- Yao Han** PHARMACOPEIAL CHARACTERIZATION OF ASPARAGINASE (abstract 25)
- Feys Lynn** Mouse xenograft model for investigating impact of radiation on lung metastasis. (abstract 26)
- Descamps Benedicte** Molecular MRI in preclinical research (abstract 27)
- Krysko Dmitri** Immunogenic cell death - apoptosis or necroptosis - does it matter? (abstract 28)
- Van der Meulen Joni** The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia (abstract 29)
- De Craene Bram** ROLE OF EMT TRANSCRIPTION FACTORS IN SKIN EPIDERMIS (abstract 30)
- Rihani Ali** CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients (abstract 31)
- Janssens Els** Phf6 plays a role in hematopoiesis and thymopoiesis in zebrafish. (abstract 32)

12.00-12.40 **Short abstract presentations**

- Rombout Ans** LPL SNPs rs301 and rs13702 predict overall survival in CLL patients (abstract 33)
- Rousseau Quentin** Impact of 10Gy irradiation on exosome release by carcinoma-associated fibroblasts (abstract 34)
- Van Bockstal Mieke** Identification of a JAK3/STAT3 passenger activation in a HER2-amplified breast cancer model of acquired resistance to lapatinib. (abstract 35)
- Wayteck Laura** HITCHHIKING NANOPARTICLES: REVERSIBLE COUPLING TO TUMOR-SPECIFIC T CELLS FOR TARGETED DRUG DELIVERY (abstract 36)
- Drebert Zuzanna** Glucocorticoid receptor modulation impacts the tumor microenvironment (abstract 37)
- Van Audenhove Isabel** Fine tuning fascin function in invadopodium formation using inhibitory and delocalizing nanobodies (abstract 38)
- Bolcaen Julie** F-18 fluoromethylcholine (FCho), F-18 fluoroethyltyrosine (FET) and F-18 fluorodeoxyglucose (FDG) for the discrimination between tumor recurrence and radiation necrosis in high-grade glioma: a μ PET study. (abstract 39)
- Clarisse Dorien** Determining the cofactor profile of the glucocorticoid receptor in lymphoid malignancies using MARCoNI (abstract 40)
- Denies Sofie** Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication (abstract 41)
- Bethuyne Jonas** The use of nanobodies® as a regulating tool for p53's transcriptional functions. (abstract 42)
- Hemeryck Lieselot** *IN VITRO AND IN VIVO* SCREENING FOR DIET-RELATED DNA ADDUCTS USING ULTRA-HIGH PERFORMANCE LIQUID CHROMATOGRAPHY COUPLED TO HIGH RESOLUTION MASS SPECTROMETRY (abstract 43)
- Baert Annelot** Development of an S-G2 micronucleus assay for the detection of in vitro chromosomal radiosensitivity in BRCA1 and BRCA2 mutation carriers. (abstract 44)
- De Leeneer Kim** The prevalence of ATM sequence variants in a Belgian (fe)(male) (breast cancer) population. (abstract 45)
- Ost Piet** The importance of the number of metastases on prostate cancer-specific survival in patients with noncastrate metastatic prostate cancer following curative treatment. (abstract 46)

- Van Praet Charles** Androgen receptor gene amplification in prostate cancer: a possible role for the stroma ? (abstract 47)
- Van Caeneghem Yasmine** Genetic correction of induced pluripotent stem cells from a Wiskott-Aldrich Syndrome patient normalizes the immune defects. (abstract 48)
- De Ryck Tine** Microbe-epithelial crosstalk in cancer therapy (abstract 49)
- Vanhee Stijn** cMYB expression during in vitro hematopoiesis from human embryonic stem cells (abstract 50)
- Gerlo Sarah** An interactomics approach to unravel IRE1 α function (abstract 51)
- Lamote Kevin** Volatile Organic Compounds as a Diagnostic Tool for Malignant Pleural Mesothelioma. (abstract 52)
- Vanden Bussche Julie** Fecal metabolite profiling as a first step towards gut health fingerprinting and disease-specific biomarkers (abstract 53)
- Lambertz Irina** ETV5 is a strong candidate driver oncogene in neuroblastoma (abstract 54)
- Antonissen Gunther** Carboplatin in avian medicine: a pharmacokinetic approach (abstract 55)
- Dakwar George** In vitro evaluation of liposomes encapsulating siRNA in SKOV-3 cells (abstract 56)
- Ghazavi Farzaneh** Prognostic relevance of BTLA/CD200 deletion in pediatric pre-B cell acute lymphoblastic leukemia (abstract 57)
- Bogaerts Eliene** TIME - DEPENDANT EFFECTS OF HYPOXIA ON LIVER PROGENITOR CELL ACTIVATION IN A MOUSE MODEL FOR HEPATOCELLULAR CARCINOMA (abstract 58)
- Goossens Steven** ZEB2 drives immature T-cell lymphoblastic leukemia development via altered IL-7 receptor signalling and enhanced tumor-initiating potential (abstract 59)
- Chevolet Ines** ENDOTHELIAL INDOLEAMINE 2,3-DIOXYGENASE IS CONSISTENTLY EXPRESSED IN THE MELANOMA IMMUNE MICRO-ENVIRONMENT AND INFLUENCES PROGNOSIS (abstract 60)
- Van Goethem Alan** Evaluation of targeted drugs in combination with the MDM2 antagonist RG7388 in neuroblastoma (abstract 61)
- Mampaey Evi** STUDY OF GENOMIC ALTERATIONS IN COLON CARCINOMA BY ARRAY COMPARATIVE GENOMIC HYBRIDIZATION (abstract 62)